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Abstract
Tricuspid valvectomy is a rare surgical intervention, and knowledge regarding long-term out-
come in children is lacking.We report a favourable outcome 11 years after tricuspid valvectomy
in early infancy without subsequent surgery or other cardiac interventions. Specific criteria for
timing of re-intervention are lacking. Application of adult tricuspid and pulmonary regurgita-
tion recommendations is helpful but has limitations.
Isolated right-sided infective endocarditis is uncommon, especially in neonates.Candida species
is the underlying micro-organism in 10% of infants with infective endocarditis. In neonates, this
results in a right-sided endocarditis in 90% of the Candida endocarditis cases.1
First choice treatment is anti-microbial medication. Surgery should be considered when large
tricuspid valve vegetation is present, when antibiotic medical treatment fails, when the infection
is caused by micro-organisms difficult to eradicate, or when refractive right heart failure is
present.2 The preferred surgical treatment is valve repair. Because of the long-term risk of devel-
oping severe right heart failure, tricuspid valvectomy is considered only in exceptional cases.3
Data on prognosis of living without tricuspid valve are scarce.3,4 Aim of this report is to share
a history of over 10-year survival after tricuspid valvectomy in infancy.
Case report
We describe the case of a female infant born at 29 weeks and 3 days of gestational age with birth
weight of 1310 kg. Details of her medical history in the first months of life have been reported
previously.5
At the age of 5 months, she was diagnosed with a thrombus obstructing the tricuspid orifice.
Cardiac surgery was performed within 24 hours after admission. The tricuspid valve could not
be repaired and valvectomy was performed. Blood cultures and thrombus examination showed
a Candida albicans, so fluconazole was initiated. The post-operative course was prolonged,
requiring maximal support with inotropic medication, diuretics, nitric oxide, and sildenafil.
Eventually she was discharged 5 weeks post-operatively using diuretics, sildenafil 8 mg/kg/
day, and fluconazole. Ultrasonography at discharge showed a dilated right heart, with normal
cardiac output and moderate reversed flow in the hepatic veins.5
The following years the girl did surprisingly well. Mild pulmonic regurgitation was noted.
Based on the measurements of pulmonic regurgitation flow velocity and the shape of the right
ventricle, there were no signs of increased pulmonary artery pressure. Because of the combined
clinical and echo findings, we did not perform invasive measurements. Sildenafil dosage was
gradually reduced and sildenafil was stopped 1 year after surgery. With the diuretics as only
medication, she had a normal growth pattern and exercise capacity during the subsequent years.
There was no progressive dilatation of the right atrium or ventricle. Until the age of 11 years old,
she stayed clinically stable without cardiac arrhythmias or signs of right heart failure.
Since the age of 11 years, exercise intolerance is present. Cardiopulmonary exercise test
showed exercise intolerance with a peak workload of 100 W (predicted 140 W, 71%) and a
decrease of peak oxygen uptake from 37 to 28 ml/kg/minute over the last 3 years (Table 1).
There were no signs of ventricular arrhythmias (as confirmed on 24-hour Holter monitoring).
Cardiac MRI showed non-progressive dilatation of the right ventricle and a normal ventricular
ejection fraction (Fig 1). Because of sub-optimal exercise performance and dilatation of the right
heart (Table 1), the question for surgical intervention arises. Based on criteria including those
used in more common situations of right ventricular dilatation, such as pulmonary regurgita-
tion, for now a conservative strategy is implemented, guided by the clinical state of the patient.
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Discussion
Information on long-term outcome after tricuspid valvectomy is
scarce. Isolated tricuspid regurgitation is commonly well tolerated
in adults.4 However, chronic severe tricuspid regurgitation may
lead to volume overload of the right ventricle, which may cause
ventricular dilatation and loss of cardiac function. Symptoms
may appear only when the disease is already advanced.4 Chronic
medical treatment for severe isolated tricuspid regurgitation in
adults consists of diuretics, and is used when clinical symptoms
of right heart failure are present. There is no evidence that the
use of diuretics improves the survival rate in these patients.4,6
Furthermore, diuretics might reduce clinical symptoms and be
successful in reducing heart failure symptoms, which might result
in delay of surgical intervention and poorer outcome.7
In our case, pulmonary hypertension, following tricuspid
valvectomy, initially persisted despite maximum support with
diuretics, inotropics, high oxygen ventilation, and inhaled NO.
Eventually, weaning from respiratory support was successful after
introduction of sildenafil 8 mg/kg/day. In the following year, the
girl was treated with diuretics and sildenafil to provide optimal pre-
load and afterload of the right ventricle. There were no side effects
reported.
Sildenafil is well studied and approved for pulmonary hyperten-
sion in adults. Currently, large trials in term and pre-term neonates
are lacking.8 A Cochrane 2017 systematic review evaluated the effi-
cacy of sildenafil monotherapy in lowering mortality in neonates
compared to placebo. Sildenafil as adjuvant therapy with other pul-
monary vasodilating products did not change mortality rates.9
Tricuspid valvectomy has never been the first choice treatment
option for endocarditis.3 In our case, clinical state and heart func-
tion remained normal for 10 years after tricuspid valvectomy. This
favourable outcome can be explained by the positive response on
medical treatment and absence of complications such as pulmo-
nary embolism in the acute phase. Furthermore, chronic medical
treatment with diuretics and new drugs such as sildenafil may have
improved the outcome.8,9
Table 1. Evolution of cardiopulmonary measurements
Age (years) 8 11
MRI
LV end-diastolic volume (ml/m²) 61 74
LV stroke volume (ml/m²/beat) 35 48
LV ejection fraction (%) 58 65
RV end-diastolic volume (ml/m²) 164 158
RV stroke volume (ml/m²) 97 98
RV ejection fraction (%) 59 62
Tricuspid regurgitation (%) 64 51
CPET
RER peak >1.2 >1.1
Maximal Power(W/kg) 2.9 2.3
VO2 peak (ml/kg/minute) 37 28
VO2 peak % of predicted value 88 76
CPET= cardiopulmonary exercise testing; LV= left ventricle; RER peak= respiratory exchange ratio at peak exercise;
RV= right ventricle.
Figure 1. Still frames of end-diastolic images of short axis orientation steady-state free-precession cine cardiac magnetic resonance imaging performed in 2014 (a) and 2017 (b).
Left ventricle is on the right-hand side of panels (a) and (b).
Cardiology in the Young 529
https://doi.org/10.1017/S1047951119000027
Downloaded from https://www.cambridge.org/core. Universiteit Gent, on 31 Mar 2020 at 10:03:35, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
There is no guideline concerning timing of surgical re-interven-
tion after tricuspid valvectomy.4 Our case shows a long-term
survival with possibility to postpone surgery, in a young child.
The AHA/ACC and ESC/EACTS guidelines for adults recom-
mend surgical intervention for primary, isolated tricuspid regurgi-
tation when patients are symptomatic or, if they are asymptomatic,
when there is progressive right ventricular dilatation and/or
dysfunction (class IIa recommendation, level of evidence C).
Surgery needs to be performed as soon as the indication is set,
to avoid irreversible right ventricular dysfunction.6,7
Follow-up includes imaging with echocardiography and MRI.
The 2017 ESC/EACTS guideline describes cut-off values of echo-
cardiographic measurements defining severe valve regurgitation in
adults.6,7 The lack of cut-off values for children is striking. This
bears resemblance to the setting of chronic right ventricle volume
overload following chronic pulmonary regurgitation, in which size
criteria of the right ventricle as indication for intervention are sub-
ject of continued debate.10 This hampers decision-making in a case
like this. In analogy to the situation in valve replacement in pulmo-
nary regurgitation, we will opt for tricuspid valve replacement if
symptoms, exercise test results, right ventricular size, and function
and/or ECG changes all point towards progressive decline of right
ventricular function.
Conclusion
This case illustrates the ability for survival in good clinical condi-
tion for more than 10 years after tricuspid valvectomy performed
in infancy. Growth, exercise capacity, and right ventricular size and
function remained within acceptable limits. Consensus criteria for
timing of re-intervention are lacking.
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